
Biologit offers AI-powered solutions for safety surveillance, focusing on pharmacovigilance, veterinary pharmacovigilance, cosmetovigilance, nutravigilance, and materiovigilance. Their core product, biologit MLM-AI, is a global and local medical literature monitoring platform designed to enhance productivity and ensure compliance. It's a validated, GxP-ready, and CFR-11 compliant SaaS platform. Biologit also provides comprehensive consultancy services for drug safety and regulatory compliance, aiming to simplify risk detection and keep products safe for consumers. They emphasize innovation, ethical practices, and collaboration.

Biologit offers AI-powered solutions for safety surveillance, focusing on pharmacovigilance, veterinary pharmacovigilance, cosmetovigilance, nutravigilance, and materiovigilance. Their core product, biologit MLM-AI, is a global and local medical literature monitoring platform designed to enhance productivity and ensure compliance. It's a validated, GxP-ready, and CFR-11 compliant SaaS platform. Biologit also provides comprehensive consultancy services for drug safety and regulatory compliance, aiming to simplify risk detection and keep products safe for consumers. They emphasize innovation, ethical practices, and collaboration.
Focus: AI-powered literature monitoring for pharmacovigilance
Headquarters: Dublin, Ireland
Founders / Leadership: Nicole Baker (CEO, co-founder); Bruno Ohana (CTO, co-founder)
Product: Biologit MLM‑AI platform (validated, GxP-ready, CFR-11 compliant SaaS)
Customers / Reach: Serves pharma companies, CROs, and PV teams in 170+ countries
Funding signal: Seed-stage funding; Enterprise Ireland listed as investor
Pharmacovigilance literature surveillance and safety signal detection across global and local/non-indexed sources.
2021
Biotechnology
3222124
“Enterprise Ireland listed as investor”
| Company |
|---|